9-aminocamptothecin has been researched along with Ovarian Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J | 1 |
| Blessing, JA; Bloss, J; Miller, DS; Schilder, J; Schilder, R; Sorosky, J; Waggoner, S | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P | 1 |
| Hassan, R; Kohn, E; Sandor, V | 1 |
| Downey, A; Hamilton, A; Hochster, H; Hornreich, G; Liebes, L; Muggia, F; Potmesil, M; Sorich, J; Wasserstrom, H | 1 |
| Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW | 1 |
2 review(s) available for 9-aminocamptothecin and Ovarian Neoplasms
| Article | Year |
|---|---|
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasms; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2000 |
2 trial(s) available for 9-aminocamptothecin and Ovarian Neoplasms
| Article | Year |
|---|---|
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms | 2005 |
3 other study(ies) available for 9-aminocamptothecin and Ovarian Neoplasms
| Article | Year |
|---|---|
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro.
Topics: Animals; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Exacerbation of pseudogout by granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Chondrocalcinosis; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Ovarian Neoplasms; Recombinant Proteins; Recurrence | 1996 |
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |